Identification of PSMD2 as a promising biomarker for pancreatic cancer patients based on comprehensive bioinformatics and in vitro studies
Authors:
Open Access
Abstract
No abstract availableKeywords
Funding Information
- National Key Research and Development Program of China (2022YFC2503600)
- National Key Research and Development Program of China (2016YFC1303600)
This publication has 42 references indexed in Scilit:
- PSMD4 drives progression of hepatocellular carcinoma via Akt/COX2 pathway and p53 inhibitionHuman Cell, 2023
- Immunosuppression, immune escape, and immunotherapy in pancreatic cancer: focused on the tumor microenvironmentCellular Oncology, 2022
- Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic CancerJAMA Oncology, 2022
- Deubiquitylase PSMD14 inhibits autophagy to promote ovarian cancer progression via stabilization of LRPPRCBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2022
- Deubiquitinase PSMD14 promotes ovarian cancer progression by decreasing enzymatic activity of PKM2Molecular Oncology, 2021
- The oncogenic role of ubiquitin specific peptidase (USP8) and its signaling pathways targeting for cancer therapeuticsArchives of Biochemistry and Biophysics, 2021
- Deubiquitinase PSMD14 enhances hepatocellular carcinoma growth and metastasis by stabilizing GRB2Cancer Letters, 2020
- The role of E3 ubiquitin ligase HECTD3 in cancer and beyondCellular and Molecular Life Sciences, 2019
- PSMD2 regulates breast cancer cell proliferation and cell cycle progression by modulating p21 and p27 proteasomal degradationCancer Letters, 2018
- Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior TherapyJAMA Oncology, 2017